newsfilter
← Latest News
GlobeNewswire·

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel